Dithiolsaccharide mucolytic agents and uses thereof
AssigneesThe Regents of the University of California, University College Dublin
InventorsStefan Oscarson, John Vincent Fahy, Irina Gitlin, Wilfred Raymond
Life of this patent
Estimating the term…
Abstract
There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.
Claims27
A method of decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of Formula II,
- wherein Formula II is represented by:
- wherein,
- R2 is —OR2A;
- R3 is —OR3A;
- R4 is OR4A;
- R5 is hydrogen;
- R6 is —SH;
- R7 is —OR7A;
- R8 is —OR8A;
- R9 is —OR9A;
- R10 is hydrogen;
- R11 is —SH;
- and
- R2A, R3A, R4A, R7A, R8A, and R9A are each independently hydrogen or unsubstituted C1-C10 alkyl;
- or a pharmaceutically acceptable salt thereof.
A method of decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of Formula II:
- wherein Formula II is represented by:
- wherein,
- R2 is —OR2A;
- R3 is —OR3A;
- R4 is —OR4A;
- R5 is hydrogen;
- R6 is —SH;
- R7 is —OR7A;
- R8 is —OR8A;
- R9 is —OR9A;
- R10 is hydrogen;
- R11 is —SH;
- and
- R2A, R3A, R4A, R7A, R8A, and R9A are each independently hydrogen or unsubstituted C1-C10 alkyl;
- or a pharmaceutically acceptable salt thereof;
- wherein the subject has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more complete mucus airway occlusions of one or more airways within one or two lungs in the subject, or wherein the subject has cicatricial pemphigoid, tuberculosis, lung cancer, emphysema, influenza, or primary ciliary dyskinesia.
A method for treatment of a condition in a subject, comprising administering to a subject in need thereof an effective amount of a compound of Formula II in combination with another therapeutic agent, wherein the therapeutic action of the therapeutic agent is enhanced by decreasing mucus elasticity or decreasing mucus viscosity, wherein the condition is chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), asthma, chronic asthma, acute asthma, bronchitis, chronic bronchitis, acute bronchitis, bronchiectasis, traction bronchiectasis, primary ciliary dyskinesia, bronchiolitis, allergic bronchopulmonary aspergillosis, pneumonia, a mechanical ventilator-associated lung injury, sinusitis, chronic rhinitis, acute sinusitis, chronic sinusitis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps, rhinorrhea, or post-nasal drip;
- and wherein Formula II is represented by:
- wherein,
- R2 is —OR2A;
- R3 is —OR3A;
- R4 is —OR4A;
- R5 is hydrogen;
- R6 is —SH;
- R7 is —OR7A;
- R8 is —OR8A;
- R9 is —OR9A;
- R10 is hydrogen;
- R11 is —SH;
- and
- R2A, R3A, R4A, R7A, R8A, and R9A are each independently hydrogen or unsubstituted C1-C10 alkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.